Logo

Exelixis Expands its Collaboration with Invenra to Develop Novel Biologics in Oncology

Share this

Exelixis Expands its Collaboration with Invenra to Develop Novel Biologics in Oncology

Shots:

  • Invenra to receive $15.0M up front along with additional fees and funding to elect up to 20 additional targets in oncology & is eligible for development- regulatory- and commercial milestones along with royalties on net sales of any approved products
  • Exelixis will own all Ab sequences discovered from the collaboration for uses in oncology or other disease areas & also get an option to obtain development and commercialization rights of Invenra’s internal pipeline programs in exchange for an opt-in fee
  • Under the terms of the original agreement (announced on May 02- 2018)- the companies are collaborating to discover and develop mono-specific and multi-specific Abs to treat cancer by using Invenra’s Abs and B-Body platforms

| Ref: Exilixis | Image: Exilixis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions